Literature DB >> 18789472

Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies.

Gretchen E Nelson1, Jerry R Sisler, Dev Chandran, Bernard Moss.   

Abstract

The vaccinia virus entry/fusion complex (EFC) is comprised of at least eight transmembrane proteins that are conserved in all poxviruses. However, neither the physical structure of the EFC nor the immunogenicity of the individual components has been determined. We prepared soluble forms of two EFC components, A28 and H2, by replacing the transmembrane domain with a signal peptide and adding a polyhistidine tail. The proteins were expressed by baculoviruses, secreted from insect cells, purified by affinity chromatography and used to raise antibodies in rabbits. The antibodies recognized the viral proteins but only the antibody to recombinant A28 bound intact virions and neutralized infectivity. Analyses with a set of overlapping peptides revealed a neutralizing epitope between residues 73 and 92 of A28. Passive immunization of mice with IgG purified from the anti-A28 serum provided partial protection against a vaccinia virus intranasal challenge, whereas IgG from the anti-H2 serum did not.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789472      PMCID: PMC2628551          DOI: 10.1016/j.virol.2008.08.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.

Authors:  Christopher C Norbury; Daniela Malide; James S Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Nat Immunol       Date:  2002-02-04       Impact factor: 25.606

2.  Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.

Authors:  Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity.

Authors:  Gretchen E Nelson; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

4.  Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.

Authors:  J W Hooper; D M Custer; E Thompson
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

5.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 6.  Smallpox vaccination: a review, part II. Adverse events.

Authors:  Vincent A Fulginiti; Arthur Papier; J Michael Lane; John M Neff; D A Henderson
Journal:  Clin Infect Dis       Date:  2003-07-10       Impact factor: 9.079

7.  Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway.

Authors:  Tatiana G Senkevich; Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene.

Authors:  Tatiana G Senkevich; Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.

Authors:  Christiana Fogg; Shlomo Lustig; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 10.  ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

Authors:  Thomas P Monath; Joseph R Caldwell; Wolfgang Mundt; Joan Fusco; Casey S Johnson; Mark Buller; Jian Liu; Bridget Gardner; Greg Downing; Paul S Blum; Tracy Kemp; Richard Nichols; Richard Weltzin
Journal:  Int J Infect Dis       Date:  2004-10       Impact factor: 3.623

View more
  23 in total

1.  Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

Authors:  Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty
Journal:  Antivir Ther       Date:  2010

2.  Transcriptional repression and RNA silencing act synergistically to demonstrate the function of the eleventh component of the vaccinia virus entry-fusion complex.

Authors:  Cindy L Wolfe; Suany Ojeda; Bernard Moss
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Assembly and disassembly of the capsid-like external scaffold of immature virions during vaccinia virus morphogenesis.

Authors:  Himani Bisht; Andrea S Weisberg; Patricia Szajner; Bernard Moss
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

4.  Vaccinia virus H7 protein contributes to the formation of crescent membrane precursors of immature virions.

Authors:  P S Satheshkumar; Andrea Weisberg; Bernard Moss
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

5.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

6.  T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

Authors:  D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

7.  Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus.

Authors:  Xiangzhi Meng; Youmin Zhong; Addie Embry; Bo Yan; Shan Lu; Guangming Zhong; Yan Xiang
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

8.  Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.

Authors:  Marissa B Wilck; Michael S Seaman; Lindsey R Baden; Stephen R Walsh; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Jane A Kleinjan; Lizanne C Noble; Kristen E Stevenson; Haesook T Kim; Raphael Dolin
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

9.  The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Authors:  Chwan Hong Foo; J Charles Whitbeck; Manuel Ponce-de-León; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.